A Study to Compare the Acute Coronary Vasodilating Effects of the sGC Stimulator Riociguat (BAY 63-2521) With the Nitric Oxide Donor Nitroglycerin in Patients With Coronary Artery Disease.

Trial Profile

A Study to Compare the Acute Coronary Vasodilating Effects of the sGC Stimulator Riociguat (BAY 63-2521) With the Nitric Oxide Donor Nitroglycerin in Patients With Coronary Artery Disease.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2013

At a glance

  • Drugs Nitroglycerin; Riociguat
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Acronyms CORONARIES
  • Most Recent Events

    • 14 Nov 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 29 Jul 2011 Planned end date changed from 1 Feb 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 29 Jul 2011 Planned initiation date changed from 1 Aug 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top